Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Eisai Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Eisai şirketinin toplam hissedar öz sermayesi ¥919.7B ve toplam borcu ¥182.3B olup, bu da borç-öz sermaye oranını 19.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥1,420.2B ve ¥500.6B dir. Eisai 'in FAVÖK'ü ¥31.7B faiz karşılama oranı -3.6 dur. Şirketin ¥303.9B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

19.8%

Borç/özkaynak oranı

JP¥182.33b

Borç

Faiz karşılama oranı	-3.6x
Nakit	JP¥303.94b
Eşitlik	JP¥919.70b
Toplam yükümlülükler	JP¥500.55b
Toplam varlıklar	JP¥1.42t

Son finansal sağlık güncellemeleri

Is Eisai (TSE:4523) A Risky Investment?

Jul 11

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Apr 11

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4523 'nin kısa vadeli varlıkları ( ¥733.2B ) kısa vadeli yükümlülüklerini ( ¥311.0B ) aşıyor.

Uzun Vadeli Yükümlülükler: 4523 şirketinin kısa vadeli varlıkları ( ¥733.2B ) uzun vadeli yükümlülüklerini ( ¥189.5B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4523 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 4523 'nin borç/öz sermaye oranı son 5 yılda 20.6% seviyesinden 19.8% seviyesine düştü.

Borç Kapsamı: 4523 'nin borcu işletme nakit akışı ( 19.1% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: 4523 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Eisai Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Eisai (TSE:4523) A Risky Investment?

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Recent updates

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

New minor risk - Earnings quality

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 17%

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

New minor risk - Share price stability

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Is Eisai (TSE:4523) A Risky Investment?

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Final dividend of JP¥80.00 announced

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Consensus EPS estimates increase by 10%, revenue downgraded

Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

High number of new directors

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Now 21% overvalued

Eisai's (TSE:4523) Dividend Will Be ¥80.00

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.

Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease Conference

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of JP¥80.00 per share at 1.9% yield

NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad Study

New minor risk - Share price stability

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South Korea

Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

Consensus EPS estimates fall by 25%

Now 21% undervalued

Upcoming dividend of JP¥80.00 per share at 2.2% yield

Third quarter 2023 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin